Switch theme
Sign up to access all valuation multiples
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
62.6K+
LTM Revenue $23.0B
LTM EBITDA $6.6B
$62.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Merck KGaA has a last 12-month revenue of $23.0B and a last 12-month EBITDA of $6.6B.
In the most recent fiscal year, Merck KGaA achieved revenue of $22.7B and an EBITDA of $6.4B.
Merck KGaA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Merck KGaA valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $22.5B | $22.7B | XXX | XXX | XXX |
| Gross Profit | $14.7B | $13.3B | XXX | XXX | XXX |
| Gross Margin | 65% | 59% | XXX | XXX | XXX |
| EBITDA | $6.1B | $6.4B | XXX | XXX | XXX |
| EBITDA Margin | 27% | 28% | XXX | XXX | XXX |
| Net Profit | $3.6B | $3.0B | XXX | XXX | XXX |
| Net Margin | 16% | 13% | XXX | XXX | XXX |
| Net Debt | $9.1B | $8.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Merck KGaA's stock price is EUR 115 (or $124).
Merck KGaA has current market cap of EUR 50.1B (or $53.8B), and EV of EUR 57.7B (or $62.0B).
See Merck KGaA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62.0B | $53.8B | XXX | XXX | XXX | XXX | $9.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Merck KGaA has market cap of $53.8B and EV of $62.0B.
Merck KGaA's trades at 2.7x LTM EV/Revenue multiple, and 9.4x LTM EBITDA.
Analysts estimate Merck KGaA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Merck KGaA and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $62.0B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | XXX | XXX |
| P/E | 18.1x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | 24.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMerck KGaA's NTM/LTM revenue growth is 4%
Merck KGaA's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Merck KGaA's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Merck KGaA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Merck KGaA and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Merck KGaA acquired XXX companies to date.
Last acquisition by Merck KGaA was XXXXXXXX, XXXXX XXXXX XXXXXX . Merck KGaA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is Merck KGaA headquartered? | Merck KGaA is headquartered in Germany. |
| How many employees does Merck KGaA have? | As of today, Merck KGaA has 62.6K+ employees. |
| Is Merck KGaA publicy listed? | Yes, Merck KGaA is a public company listed on ETR. |
| What is the stock symbol of Merck KGaA? | Merck KGaA trades under MRK ticker. |
| When did Merck KGaA go public? | Merck KGaA went public in 1995. |
| Who are competitors of Merck KGaA? | Similar companies to Merck KGaA include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Merck KGaA? | Merck KGaA's current market cap is $53.8B |
| What is the current revenue of Merck KGaA? | Merck KGaA's last 12-month revenue is $23.0B. |
| What is the current EBITDA of Merck KGaA? | Merck KGaA's last 12-month EBITDA is $6.6B. |
| What is the current EV/Revenue multiple of Merck KGaA? | Current revenue multiple of Merck KGaA is 2.7x. |
| What is the current EV/EBITDA multiple of Merck KGaA? | Current EBITDA multiple of Merck KGaA is 9.4x. |
| What is the current revenue growth of Merck KGaA? | Merck KGaA revenue growth between 2023 and 2024 was 1%. |
| Is Merck KGaA profitable? | Yes, Merck KGaA is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
